A recent study suggests that individuals who stop using popular slimming jabs like Mounjaro or Wegovy tend to recover shed pounds at a significantly accelerated pace than those who stop conventional lifestyle regimens.
Research printed in a prominent medical journal points out that while obese individuals frequently drop substantial amounts of their body weight while undergoing treatment, the weight comes back at an average rate of 0.8 kg per month after stopping.
"People using such drugs need to be cognizant of the danger of quick rebound weight gain when the therapy ends," stated lead investigator Dr. Susan Jebb.
That rate of regain means a return to starting mass in about a year and a half.
Comparing Therapies
The study, which examined dozens of trials involving thousands of participants, contrasted the outcomes of GLP-1 agonists with older methods.
The team emphasize that individuals who lose weight through dieting usually see a slower creep back—perhaps 0.1 kg a month—post-intervention.
Understanding the Rapid Rebound
Experts believe the mechanism of the drugs accounts for the accelerated weight return.
GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Artificially providing GLP-1 levels far above than the body's typical production might result in the body to produce less of its endogenous GLP-1, and could lessen responsiveness to its effects," explained Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this medication results in appetite is no longer kept in check, making excessive eating a significant risk."
An Ongoing Condition?
Medical guidelines suggest the jabs for individuals with obesity-related medical conditions, alongside recommended diet and exercise modifications.
Many experts say that, given the significant potential of weight regain, the treatment should be considered ongoing.
This view is echoed by drug manufacturers, who state that the findings "underscore the long-term nature of obesity," comparing it to managing diseases like high blood pressure.
User Testimonies
Users who have come off the medication describe a intense return of cravings.
"I experienced a trigger that goes on and I was suddenly ravenous," recalled a patient.
This challenge is compounded if users have not developed sustainable lifestyle or habit changes during treatment.
Widespread Adoption
Survey data suggest that millions of people in the UK have tried these injections in the past year, with desire being substantial.
- Use is greater among women compared to males.
- The middle-aged age group shows the greatest level of interest.
- Many obtain the medications through private healthcare rather than the NHS.
Finally, researchers emphasize that while GLP-1 drugs are powerful agents for shedding pounds, they are not a permanent cure and lasting health benefits likely depends on integrated behavioural management.
